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www.jacc-interventions.org to view.Percutaneous Left Atrial Appendage Closure With the Watchman Device:
Long-Term Results Up to 5 Years1915Jens Wiebe, Jennifer Franke, Katharina Lehn, Ilona Hofmann, Laura Vaskelyte,
Stefan Bertog, Horst SievertPercutaneous left atrial appendage (LAA) closure is an alternative to oral anticoagulation for
prevention of cardioembolic events in patients with atrial ﬁbrillation. The authors evaluated 102
patients with minimum CHA2DS2-VASc scores of 1 who underwent LAA closure with the Watchman
device between June 2006 and August 2010 with regard to long-term outcomes. During a mean
follow-up period of 3.0  1.6 years, the annual rates of transient ischemic attack, stroke,
intracranial hemorrhage, were 0.7%, 0.7%, and 1.1%, respectively. These low ischemic events rates
demonstrate the effectiveness of LAA closure with the Watchman device during long-term follow-up.n EDITORIAL COMMENT
Closing the Oval Door 1922
David R. Holmes, Jr., Douglas L. Packer
Bleeding Outcomes After Left Atrial Appendage Closure Compared With
Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN
Randomized Trial Experience1925Matthew J. Price, Vivek Y. Reddy, Miguel Valderrábano, Jonathan L. Halperin,
Douglas N. Gibson, Nicole Gordon, Kenneth C. Huber, David R. Holmes, Jr.Left atrial appendage (LAA) closure with the WATCHMAN device (Boston Scientiﬁc, Natick,
Massachusetts) followed by discontinuation of long-term oral anticoagulation is an effective
alternative to long-term warfarin anticoagulation for the prevention of thromboembolic events. We
conducted a pooled, patient-level analysis of the 2 randomized trials that compared WATCHMAN
LAA closure with extended warfarin therapy to assess the effect of treatment on long-term
bleeding. LAA closure signiﬁcantly reduced bleeding beyond the procedural period, particularly
after 6 months, when patients assigned to device therapy could discontinue adjunctive
pharmacotherapy. The favorable effect of LAA closure on long-term bleeding should be considered
when selecting a stroke prevention strategy for AF patients.n EDITORIAL COMMENT
Go Set a Watchman? 1933
John A. BittlCONTINUED ON PAGE A-13
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DECEMBER 28, 2015 VOLUME 8, NUMBER 15Changes in Left Atrial Appendage Dimensions Following Volume Loading During
Percutaneous Left Atrial Appendage Closure1935Ryan J. Spencer, Peggy DeJong, Peter Fahmy, Mathieu Lempereur, Michael Y.C. Tsang,
Kenneth G. Gin, Pui K. Lee, Parvathy Nair, Teresa S.M. Tsang, John Jue, Jacqueline SawThe safety and efﬁcacy of left atrial appendage (LAA) closure relies on accurate device sizing, which
necessitates accurate measurement of LAA dimensions. LAA size may change with volume status,
thus intraprocedural measurements taken in the fasting state may underestimate true LAA size.
This study provides evidence that volume loading during percutaneous LAA closure increases the
oriﬁce width, and depth of the LAA, supporting previous work demonstrating high LAA
compliance. In this study, width and depth measurements increased by w2 mm after volume
loading, resulting in the selection of a larger device. Operators should consider volume loading
before ﬁnal device selection.n EDITORIAL COMMENT
Measure Twice, Close Once: Effect of Volume Loading on
Left Atrial Appendage Closure1942Sameer Gafoor, Mayank Agrawal, Horst Sievert
Regional Systems of Care to Optimize Outcomes in Patients Undergoing Transcatheter
Aortic Valve Replacement1944Dion Stub, Sandra Lauck, May Lee, Min Gao, Karin Humphries, Albert Chan,
Anson Cheung, Richard Cook, Anthony Della Siega, Jonathon Leipsic, Jay Charania,
Danny Dvir, Tim Latham, Jopie Polderman, Simon Robinson, Daniel Wong,
Christopher R. Thompson, David Wood, Jian Ye, John WebbTranscatheter aortic valve replacement (TAVR) has become an accepted treatment option for
patients with severe aortic stenosis who are at high surgical risk. The authors describe the
implementation and outcomes of a regional system of care for TAVR in British Columbia, Canada.
A total of 583 patients underwent TAVR in British Columbia between 2012 and 2014. Transfemoral
access was performed 85.6% of cases. All-cause in-hospital mortality and disabling stroke
occurred in 3.1% and 1.9%, respectively. Median length of stay was 3 days (interquartile range: 3
to 6 days), with 92.8% of patients discharged directly home. This experience demonstrates the
potential beneﬁts to a regional system of care for TAVR.n EDITORIAL COMMENT
Balancing Optimal Outcomes With Access to Care: It Can Be Done! 1952
Michael MackCONTINUED ON PAGE A-14
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DECEMBER 28, 2015 VOLUME 8, NUMBER 15CORONARY The Association of Previous Revascularization With In-Hospital Outcomes in Acute
Myocardial Infarction Patients: Results From the National Cardiovascular Data Registry1954Luis Gruberg, Anne S. Hellkamp, Laine E. Thomas, James A. de Lemos,
Benjamin M. Scirica, Anthony Hilliard, Jonathan R. Enriquez, Amr Mohsen,
Tracy Y. WangAnalysis of 15,628 patients with ST-segment myocardial infarction who underwent primary
percutaneous coronary intervention showed that patients with previous coronary artery bypass
surgery were more likely to have reperfusion delays compared with patients with no previous
revascularization. Unadjusted in-hospital major adverse cardiovascular or cerebrovascular event
risk was signiﬁcantly higher in patients with a history of coronary artery bypass surgery compared
with patients without previous revascularization, yet risk-adjusted, in-hospital outcomes were
similar to those without previous revascularization. No signiﬁcant differences in reperfusion
timeliness and in-hospital outcomes were seen in patients with a history of percutaneous coronary
intervention compared with patients without previous revascularization.n EDITORIAL COMMENT
Timely Primary Percutaneous Coronary Intervention:
A Call to Action in the Post-Coronary Artery Bypass Graft Patient1963John S. Douglas, Jr.
Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion
in ST-Segment Elevation Myocardial Infarction: An Analysis From HORIZONS-AMI Trial
(Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)1966Abhiram Prasad, Bernard J. Gersh, Roxana Mehran, Bruce R. Brodie, Sorin J. Brener,
José M. Dizon, Alexandra J. Lansky, Bernhard Witzenbichler, Ran Kornowski,
Giulio Guagliumi, Dariusz Dudek, Gregg W. StoneWe examined the effect of symptom onset-to-balloon time (SBT) and door-to-balloon time (DBT) on
myocardial reperfusion utilizing ST-segment elevation resolution (STR) and the myocardial blush
grade (MBG) in 2,056 STEMI patients in the (Harmonizing Outcomes with Revascularization and
Stents in Acute Myocardial Infarction) trial. Absent microvascular patients perfusion (MBG 0/1) and
STR (<30%) after primary PCI was signiﬁcantly more common in patients with longer SBT, both in
low and high clinical-risk proﬁle. SBT was an independent predictor of MBG 0/1 and absent STR.
DBT was an independent predictor of MBG 0/1. The ﬁndings suggest that delay in mechanical
reperfusion therapy during STEMI is associated with greater coronary microvascular injury.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Door-to-Balloon Time as a Process Metric for Treatment
of ST-Segment Elevation Myocardial Infarction: Time to “Tap Out”?1975Michael A. KutcherCONTINUED ON PAGE A-15
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DECEMBER 28, 2015 VOLUME 8, NUMBER 15Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing
Percutaneous Coronary Intervention? “Window” Analysis From the ADAPT-DES Study
(Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents)1978Ajay J. Kirtane, Puja B. Parikh, Thomas D. Stuckey, Ke Xu, Bernhard Witzenbichler,
Giora Weisz, Michael J. Rinaldi, Franz-Josef Neumann, D. Christopher Metzger,
Timothy D. Henry, David A. Cox, Peter L. Duffy, Bruce R. Brodie, Ernest L. Mazzaferri, Jr.,
Rupa Parvataneni, Akiko Maehara, Philippe Généreux, Roxana Mehran, Gregg W. StoneThis study sought to determine whether there is an ideal level of platelet reactivity to optimize safety
and efﬁcacy within the large, multicenter ADAPT-DES (Assessment of Dual AntiPlatelet Therapy With
Drug-Eluting Stents) study of 8,582 patients receiving successful drug-eluting stent implantation.
There was a monotonic association between successively higher P2Y12 reaction units (PRU)
quintiles and stent thrombosis, whereas for clinically-relevant bleeding, the greatest risk occurred
in the lowest PRU quintile, with similar risks across the 4 higher quintiles. These relationships
remained signiﬁcant in fully adjusted multivariable analyses; however, there were no signiﬁcant
independent associations between the level of PRU and mortality.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
A Bigger Look Into the “Therapeutic Window” of Platelet Reactivity to Adenosine
Diphosphate1988Udaya S. Tantry, Paul A. Gurbel
Limitation of Infarct Size and No-Reﬂow by Intracoronary Adenosine Depends
Critically on Dose and Duration1990Tuncay Yetgin, André Uitterdijk, Maaike te Lintel Hekkert, Daphne Merkus,
Ilona Krabbendam-Peters, Heleen M.M. van Beusekom, Robert Falotico,
Patrick W. Serruys, Olivier C. Manintveld, Robert-Jan M. van Geuns,
Felix Zijlstra, Dirk J. DunckerCurrently, there is no effective adjuvant pharmacotherapy to limit lethal reperfusion injury in the
clinical setting. Clinical studies investigating high-dose intracoronary adenosine during early
reperfusion have been largely negative. In the present study, the authors investigated the effects
of adenosine-administered during early reperfusion in swine. Whereas a high-dose bolus injection
at reperfusion did not afford protection, a high-dose prolonged intracoronary infusion of
adenosine, starting just prior to reperfusion, did limit infarct size and no-reﬂow. These ﬁndings
support a role for adenosine in limiting no-reﬂow and infarct size, but they underscore the
importance of optimal dosing and duration.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Adenosine as Adjunctive Therapy for Acute Myocardial Infarction:
Is It Time for Another Clinical Trial?2000Michael RagostaCONTINUED ON PAGE A-16
CONTENTS
PAGE A-16
DECEMBER 28, 2015 VOLUME 8, NUMBER 15Effect of Drug-Coated Balloons in Native Coronary Artery Disease Left With a Dissection 2003
Bernardo Cortese, Pedro Silva Orrego, Pierfrancesco Agostoni, Dario Buccheri,
Davide Piraino, Giuseppe Andolina, Romano Giuseppe SeregniSecond-generation drug-coated-balloons (DCB) for the treatment of native coronary lesions may be
associated with residual coronary dissection. In this study, the authors investigated the destiny of
coronary dissections left after DCB percutaneous coronary intervention (PCI). Of the 156 patients treated
with DCB during the study period in our centers, PCI of 52 patients resulted in a ﬁnal non–ﬂow-limiting
dissection. At angiographic follow-up after 6 months, we observed the healing of 93.8% of such
dissections, no cases of thrombosis/vessel occlusion, and a rate of binary restenosis of 6.2%. DCB use
resulting in a ﬁnal dissection was safe and not associated with an increased need for reintervention.n EDITORIAL COMMENT
Drug-Coated Balloon Angioplasty for De Novo Stenosis:
The Balloon is Back.Reloaded!2010Robert A. Byrne, Michael JonerPERIPHERAL Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs
With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline2013Ling Zhou, Juan Zhang, Xiao-Min Jiang, Du-Jiang Xie, Jin-Song Wang, Li Li, Bin Li,
Zhi-Mei Wang, Alexander M.K. Rothman, Allan Lawrie, Shao-Liang ChenPulmonary artery denervation was associated with signiﬁcant improvements in hemodynamics and
pulmonary artery remodeling, resulting from permanent sympathetic nerve injury, inhibition of
inﬂammation, abnormal proliferation, and vasoconstriction in an experimental pulmonary arterial
hypertension model.n EDITORIAL COMMENT
Pulmonary Artery Denervation for Pulmonary Artery Hypertension 2024
Lewis J. RubinTRANSLATIONAL How Can We Help a Patient With a Small Failing Bioprosthesis? An In Vitro Case Study 2026
Prem A. Midha, Vrishank Raghav, Jose F. Condado, Sivakkumar Arjunon,
Domingo E. Uceda, Stamatios Lerakis, Vinod H. Thourani, Vasilis Babaliaros,
Ajit P. YoganathanIn this in vitro study, a balloon-expandable transcatheter aortic valve was implanted in a small
surgical bioprosthesis (valve-in-valve). As the position of the transcatheter valve was moved
further supra-annular, transvalvular pressure gradients were reduced, but the risk for valve
thrombosis and embolization also increased. A 3- to 6-mm supra-annular deployment could
provide a balance between risks and beneﬁts and should be investigated further in clinical studies.n EDITORIAL COMMENT
Treatment of Small Surgical Valves: Clinical Considerations for Achieving
Optimal Results in Valve-in-Valve Procedures2034Danny DvirCONTINUED ON PAGE A-17
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DECEMBER 28, 2015 VOLUME 8, NUMBER 15IMAGES IN
INTERVENTIONGluing of an Aortic Perforation During Transcatheter Aortic Valve Replacement:
An Alternative Treatment for Annular Rupture?2037Nicolas Piliero, Fréderic Thony, Gerald Vanzetto, Gilles Barone-Rochette
Calciﬁed Neoatherosclerosis Causing “Undilatable” In-Stent Restenosis:
Insights of Optical Coherence Tomography and Role of Rotational Atherectomy2039Teresa Bastante, Fernando Rivero, Javier Cuesta, Fernando Alfonso
n ONLINE FEATURE 2-Year Follow-Up of the First in Human Transapical Implantation
of Transcatheter Inverted Aortic Valve to Treat Native Mitral Valve Stenosise247Vaikom Subramanian Mahadevan, Imthiaz Manoly, Ragheb Hasan
n ONLINE FEATURE Progression of Intimal Hyperplasia and Multiple-Channel
Formation After Fogarty Thrombectomy: Insight Into Vasculopathy From
Optical Coherence Tomography and Intravascular Ultrasound Findingse251Yoshiya Yamamoto, Osami Kawarada, Shingo Sakamoto, Koichiro Harada,
Teruo Noguchi, Hisao Ogawa, Satoshi Yasuda
n ONLINE FEATURE Overlapping-Stent Intervention Treatment of a
Giant Right Coronary Artery Pseudoaneurysme255Hai-Long Dai, Xue-Feng Guang, Li-Hong Jiang, Qiang Xue, Wei-Hua Zhang
n ONLINE FEATURE Intimomedial Abrasion Complicating Coronary Thrombus
Aspiratione257Milosz Jaguszewski, Brunilda Alushi, Leif-Christopher Engel, Juan Luis Gutiérrez-Chico
n ONLINE FEATURE An Unusual Case of Stent-in-Stent Thrombosis e261
Jiang Ming Fam, W. den Dekker, Paul de Graaf, Evelyn Regar
n ONLINE FEATURE Catheter-Based Edge-to-Edge Mitral Valve Repair After
Partial Rupture of Surgical Annuloplasty Ringe263Felipe C. Fuchs, Christoph Hammerstingl, Nikos Werner, Eberhard Grube,
Georg Nickenig
n ONLINE FEATURE Thoracoscopic Atriclip Closure of Left Atrial Appendage
After Failed Ligation via LARIATe265Sam G. Aznaurov, Stephen K. Ball, Christopher R. Ellis
n ONLINE FEATURE Emergent Extracorporeal Circulation for Refractory Ventricular
Fibrillation via Transapical Cannulation as an Arterial Line During Transapical
Transcatheter Aortic Valve Replacemente269Keisuke Nakabayashi, Masaaki Koide, Hisayuki Okada, Toshiaki Oka
n ONLINE FEATURE THESE ARTICLES DO NOT APPEAR IN THE PRINTED ISSUE.
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THE EDITOROverexpansion of the SAPIEN 3 Transcatheter Heart Valve: A Feasibility Study 2041
Anupama Shivaraju, Susheel Kodali, Christian Thilo, Ilka Ott, Heribert Schunkert,
Wolfgang von Scheidt, Martin B. Leon, Adnan Kastrati, Albert M. Kasel
ECG-Independent Calculation of Instantaneous Wave-Free Ratio 2043
Ricardo Petraco, Sayan Sen, Sukhjinder Nijjer, Iqbal S. Malik, Ghada W. Mikhail,
Rasha Al-Lamee, Christopher Cook, Christopher Baker, Rafﬁ Kaprielian, Rodney A. Foale,
Jamil Mayet, Darrel P. Francis, Justin E. DaviesEDITOR’S PAGE The Journal Is Now Biweekly 2047
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